These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

738 related items for PubMed ID: 22179489

  • 1. Iron status and analysis of efficacy and safety of ferric carboxymaltose treatment in patients with inflammatory bowel disease.
    Beigel F, Löhr B, Laubender RP, Tillack C, Schnitzler F, Breiteneicher S, Weidinger M, Göke B, Seiderer J, Ochsenkühn T, Brand S.
    Digestion; 2012; 85(1):47-54. PubMed ID: 22179489
    [Abstract] [Full Text] [Related]

  • 2. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.
    Kulnigg S, Stoinov S, Simanenkov V, Dudar LV, Karnafel W, Garcia LC, Sambuelli AM, D'Haens G, Gasche C.
    Am J Gastroenterol; 2008 May; 103(5):1182-92. PubMed ID: 18371137
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
    Geisser P, Rumyantsev V.
    Arzneimittelforschung; 2010 May; 60(6a):373-85. PubMed ID: 20648929
    [Abstract] [Full Text] [Related]

  • 4. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease.
    Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, Chopey IV, Gutzwiller FS, Riopel L, Gasche C, FERGI Study Group.
    Gastroenterology; 2011 Sep; 141(3):846-853.e1-2. PubMed ID: 21699794
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR.
    Arzneimittelforschung; 2010 Sep; 60(6a):386-98. PubMed ID: 20648930
    [Abstract] [Full Text] [Related]

  • 6. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA, Goodnough LT.
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [Abstract] [Full Text] [Related]

  • 7. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators.
    N Engl J Med; 2009 Dec 17; 361(25):2436-48. PubMed ID: 19920054
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P, Banké-Bochita J.
    Arzneimittelforschung; 2010 Dec 17; 60(6a):362-72. PubMed ID: 20648928
    [Abstract] [Full Text] [Related]

  • 9. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U, Illigens BM, Siepmann T, Arneth B, Siegert G, Siegels D, Heigl F, Hettich R, Ramlow W, Prophet H, Bornstein SR, Julius U.
    Atheroscler Suppl; 2015 May 17; 18():199-208. PubMed ID: 25936327
    [Abstract] [Full Text] [Related]

  • 10. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O, Mickisch O, Seidler U, de Weerth A, Dignass AU, Herfarth H, Reinshagen M, Schreiber S, Junge U, Schrott M, Stein J.
    Am J Gastroenterol; 2005 Nov 17; 100(11):2503-9. PubMed ID: 16279906
    [Abstract] [Full Text] [Related]

  • 11. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S, Maltez C, Lopes AI.
    Scand J Gastroenterol; 2017 Jan 17; 52(1):29-33. PubMed ID: 27576956
    [Abstract] [Full Text] [Related]

  • 12. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease.
    Evstatiev R, Alexeeva O, Bokemeyer B, Chopey I, Felder M, Gudehus M, Iqbal T, Khalif I, Marteau P, Stein J, Gasche C, FERGI Study Group.
    Clin Gastroenterol Hepatol; 2013 Mar 17; 11(3):269-77. PubMed ID: 23078888
    [Abstract] [Full Text] [Related]

  • 13. Oxidative stress markers in predicting response to treatment with ferric carboxymaltose in nondialysis chronic kidney disease patients.
    Prats M, Font R, García C, Muñoz-Cortés M, Cabré C, Jariod M, Romeu M, Giralt M, Martinez-Vea A.
    Clin Nephrol; 2014 Jun 17; 81(6):419-26. PubMed ID: 24691014
    [Abstract] [Full Text] [Related]

  • 14. A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Onken JE, Bregman DB, Harrington RA, Morris D, Acs P, Akright B, Barish C, Bhaskar BS, Smith-Nguyen GN, Butcher A, Koch TA, Goodnough LT.
    Transfusion; 2014 Feb 17; 54(2):306-15. PubMed ID: 23772856
    [Abstract] [Full Text] [Related]

  • 15. Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice.
    Stein J, Aksan A, Klemm W, Nip K, Weber-Mangal S, Dignass A.
    J Crohns Colitis; 2018 Jun 28; 12(7):826-834. PubMed ID: 29955835
    [Abstract] [Full Text] [Related]

  • 16. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial.
    Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R.
    Am J Obstet Gynecol; 2008 Oct 28; 199(4):435.e1-7. PubMed ID: 18928998
    [Abstract] [Full Text] [Related]

  • 17. Anemia and iron deficiency in inflammatory bowel disease: an open, prospective, observational study on diagnosis, treatment with ferric carboxymaltose and quality of life.
    Befrits R, Wikman O, Blomquist L, Hjortswang H, Hammarlund P, Bajor A, Klintman D, Blom H.
    Scand J Gastroenterol; 2013 Sep 28; 48(9):1027-32. PubMed ID: 23889159
    [Abstract] [Full Text] [Related]

  • 18. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA, Bregman DB, Harrington RA, Morris D, Butcher A, Koch TA, Goodnough LT, Wolf M, Onken JE.
    Nephrol Dial Transplant; 2010 Jul 28; 25(7):2368-75. PubMed ID: 20466657
    [Abstract] [Full Text] [Related]

  • 19. TREATMENT OF ANEMIA AND IMPROVEMENT OF QUALITY OF LIFE AMONG PATIENTS WITH CROHN'S DISEASE: experience using ferric carboxymaltose.
    Sobrado CW, Cançado RD, Sobrado LF, Frugis MO, Sobrado MF.
    Arq Gastroenterol; 2015 Dec 28; 52(4):255-9. PubMed ID: 26840464
    [Abstract] [Full Text] [Related]

  • 20. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial.
    Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A.
    Obstet Gynecol; 2007 Aug 28; 110(2 Pt 1):267-78. PubMed ID: 17666600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.